Methods for detecting in vitro thrombolysis

By preparing in vitro thrombus blocks by labeling fibrinogen with fluorescein and combining fluorescent labeling with microscopic detection, the problem of low sensitivity in existing in vitro thrombolysis detection methods is solved, and rapid and accurate thrombolysis detection is achieved.

CN117783511BActive Publication Date: 2026-11-17SHANGHAI SHUIDA TECHNOLOGY TRANSFER CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202311855650.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-29
Publication Date
2026-11-17
Estimated Expiration
2043-12-29

AI Technical Summary

Technical Problem

Existing methods for detecting in vitro thrombolysis are not very sensitive and take a long time, making it difficult to monitor thrombolysis quickly and accurately.

Method used

In vitro thrombi were prepared by mixing fibrinogen labeled with fluorescein with plasma. The thrombus structure was analyzed by fluorescence labeling and scanning electron microscopy. The plasma fluorescence intensity was detected by fluorescence microscopy and fluorescence spectrophotometer to analyze the dissolution of the thrombus.

Benefits of technology

It enables rapid and sensitive detection of in vitro thrombolysis, improving detection efficiency and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117783511B_ABST
    Figure CN117783511B_ABST
Patent Text Reader

Abstract

This invention relates to biotechnology and discloses a method for detecting in vitro thrombolysis. The method includes: fluorescently labeling fibrinogen with a fluorescein to obtain fluorescein-labeled fibrinogen; mixing the fluorescein-labeled fibrinogen with plasma to obtain mixture I; mixing mixture I, thrombin, soluble calcium salt, and a solvent and incubating to obtain a plasma clot; fixing the plasma clot with glutaraldehyde solution to obtain an in vitro thrombus; degrading the in vitro thrombus by mixing it with a thrombolytic enzyme and physiological saline to obtain a degraded in vitro thrombus; determining the structure of the thrombus in the degraded in vitro thrombus and analyzing the relationship between the thrombus structure and thrombus degradation; and detecting the plasma fluorescence intensity of the degraded in vitro thrombus and analyzing the relationship between the plasma fluorescence intensity and thrombus degradation. This method enables rapid and sensitive detection of in vitro thrombus dissolution.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to biotechnology, and more specifically to a method for detecting in vitro thrombolysis. Background Technology

[0002] Thrombotic diseases have a high clinical incidence and a high rate of disability and mortality, especially cardiovascular and cerebrovascular diseases such as stroke and myocardial infarction caused by thromboembolism, which seriously threaten human health and life. Thrombosis is the process by which blood coagulates in the heart and blood vessels, or certain formed elements in the blood aggregate to form a solid mass, which is called a thrombus. Currently, the generally accepted mechanism of thrombus formation is still related to three factors: damage to the cardiovascular endothelium, changes in blood flow, and changes in the physicochemical properties of blood. Strictly speaking, the thrombi used in in vitro studies should be called extravascular coagulation and blood clots, which are obtained by taking blood from animals or humans, coagulating it into a blood clot in vitro, and then placing it in a quiescent state, or by conducting studies in a device that simulates human blood circulation.

[0003] In vitro thrombus preparation is an important experimental method widely used in studies of thrombus formation and dissolution. By simulating the activation process of the in vivo coagulation system, thrombi are prepared in vitro and fluorescently labeled, allowing for real-time monitoring of thrombus dissolution and the study of its mechanisms, regulatory factors, and the development of related diseases. However, existing methods for detecting thrombus dissolution efficacy suffer from low sensitivity and long detection times.

[0004] Therefore, there is an urgent need to provide a method for detecting in vitro thrombolysis. Summary of the Invention

[0005] The purpose of this invention is to overcome the problems existing in the prior art and provide a method for detecting thrombi in vitro, which can achieve rapid and sensitive detection of the dissolution of thrombi in vitro.

[0006] To achieve the above objectives, the present invention provides a method for detecting in vitro thrombolysis, the method comprising the following steps: (1) Fluorescent labeling of fibrinogen with fluorescein to obtain fluorescein-labeled fibrinogen, and mixing the fluorescein-labeled fibrinogen with plasma to obtain mixture I; (2) Mix the above-mentioned mixture I, thrombin, soluble calcium salt and solvent and incubate to obtain a plasma clot; mix the plasma clot with glutaraldehyde solution and fix it to obtain an in vitro thrombus; (3) The in vitro thrombus, thrombolytic enzyme and physiological saline are mixed and degraded to obtain the degraded in vitro thrombus; (4) Determine the structure of the thrombus in the degraded in vitro thrombus block and analyze the relationship between the structure of the thrombus and thrombus degradation; detect the plasma fluorescence intensity of the degraded in vitro thrombus block and analyze the relationship between the plasma fluorescence intensity and thrombus degradation.

[0007] Preferably, in step (1), the fluorescein is FITC and / or TRITC.

[0008] Preferably, the plasma is selected from at least one of rat plasma, dog plasma, and human plasma.

[0009] Preferably, the volume ratio of the fluorescein-labeled fibrinogen to the plasma is 1:3-7.

[0010] Preferably, the method further includes: diluting the mixture I obtained in step (1) by 4-8 times with physiological saline.

[0011] Preferably, in step (2), the solvent is a buffer solution, and more preferably a Tris-HCl buffer solution.

[0012] Preferably, the soluble calcium salt is selected from at least one of calcium chloride, calcium nitrate and calcium sulfate, and more preferably calcium chloride.

[0013] Preferably, relative to 1 mL of the solvent, the amount of mixture I added is 0.8-0.9 mL, the enzyme activity of the thrombin is 0.3-0.6 U, and the amount of the soluble calcium salt added is 6-8 μmol.

[0014] Preferably, the incubation conditions include at least the following: a temperature of 35-40°C and a time of 1-3 hours.

[0015] Preferably, the concentration of glutaraldehyde in the glutaraldehyde solution is 2-3 by volume.

[0016] Preferably, the fixed conditions include at least the following: temperature of 25-30°C and time of 2-4 hours.

[0017] Preferably, in step (3), the thrombolytic enzyme is selected from at least one of urokinase, nattokinase, streptokinase, alteplase and reteplase, and is more preferably urokinase.

[0018] Preferably, the thrombolytic enzyme has an activity of 1-2 U relative to 1 mL of the physiological saline, and the amount of the in vitro thrombus is 0.5-1.0 g.

[0019] Preferably, the degradation conditions include at least the following: a temperature of 35-40°C and a time of 6-24 hours.

[0020] Preferably, in step (4), the structure of the thrombus is analyzed by scanning electron microscopy; before detection, 6-10 nm of palladium is sprayed onto the degraded in vitro thrombus block.

[0021] Preferably, the structure of the thrombus is observed using a fluorescence microscope.

[0022] Preferably, a fluorescence spectrophotometer is used to detect the plasma fluorescence intensity of the degraded in vitro thrombus.

[0023] The beneficial effects of the present invention through the above technical solution are as follows: The method for detecting in vitro thrombolysis provided by this invention prepares an in vitro thrombus block by labeling fibrinogen with fluorescein, and fluorescently labels the thrombus in the in vitro thrombus block; during the degradation process of the in vitro thrombus block, thrombolytic enzyme and physiological saline, the dissolution of the thrombus can be detected rapidly and sensitively based on the structure of the fluorescently labeled thrombus.

[0024] Other features and advantages of the present invention will be described in detail in the following detailed description section. Attached Figure Description

[0025] Figure 1 This is a scanning electron microscope image of the degraded in vitro thrombus from Comparative Example 2; Figure 2 This is a scanning electron microscope image of the degraded in vitro thrombus from Example 2; Figure 3 This is a scanning electron microscope image of the degraded in vitro thrombus from Example 3; Figure 4 This is a fluorescence microscope image of the degraded in vitro thrombus from Comparative Example 2; Figure 5 This is a fluorescence microscope image of the degraded in vitro thrombus from Example 2; Figure 6 This is a fluorescence microscope image of the degraded in vitro thrombus from Example 3. Detailed Implementation

[0026] The following provides a detailed description of specific embodiments of the present invention. It should be understood that the specific embodiments described herein are for illustrative and explanatory purposes only and are not intended to limit the scope of the invention.

[0027] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0028] This invention provides a method for detecting in vitro thrombolysis, the method comprising the following steps: (1) Fluorescent labeling of fibrinogen with fluorescein to obtain fluorescein-labeled fibrinogen, and mixing the fluorescein-labeled fibrinogen with plasma to obtain mixture I; (2) Mix the above-mentioned mixture I, thrombin, soluble calcium salt and solvent and incubate to obtain a plasma clot; mix the plasma clot with glutaraldehyde solution and fix it to obtain an in vitro thrombus; (3) The in vitro thrombus, thrombolytic enzyme and physiological saline are mixed and degraded to obtain the degraded in vitro thrombus; (4) Determine the structure of the thrombus in the degraded in vitro thrombus block and analyze the relationship between the structure of the thrombus and thrombus degradation; detect the plasma fluorescence intensity of the degraded in vitro thrombus block and analyze the relationship between the plasma fluorescence intensity and thrombus degradation.

[0029] During their research, the inventors discovered that by preparing in vitro thrombus blocks through fluorescein labeling of fibrinogen, and by fluorescently labeling the thrombi in the in vitro thrombus blocks, and by mixing the in vitro thrombus blocks, thrombolytic enzymes, and physiological saline for degradation, the dissolution of the thrombi can be rapidly and sensitively detected based on the structure of the fluorescently labeled thrombi.

[0030] According to the present invention, preferably, in step (1), the fluorescein is fluorescein isothiocyanate (FITC) and / or rhodamine tetramethylisothiocyanate (TRITC). Specifically, the fluorescein can be FITC, TRITC, or a combination of both. The inventors have found that, in this preferred embodiment, using fluorescein to label fibrinogen, and thus labeling thrombi in in vitro thrombus blocks, facilitates observation of thrombus dissolution, significantly improving the sensitivity and efficiency of detecting in vitro thrombus dissolution.

[0031] According to the present invention, in order to further improve the efficiency and yield of preparing in vitro thrombi, preferably, the plasma is selected from at least one of mouse plasma, canine plasma, and human plasma. Specifically, the mouse is a C57BL / 6J mouse, and the dog is a beagle. It should be noted that the plasma is venous blood.

[0032] According to the present invention, in order to further improve the labeling effect of fluorescein on fibrinogen, preferably, the volume ratio of the fluorescein-labeled fibrinogen to the plasma is 1:3-7, specifically 1:3, 1:4, 1:5, 1:6, 1:7, or any value between the two aforementioned values.

[0033] According to the present invention, in order to further improve the efficiency and yield of preparing in vitro thrombus blocks, preferably, the method further includes: diluting the mixture I obtained in step (1) with physiological saline by 4-8 times, specifically 4 times, 6 times, 8 times, or any value between the two aforementioned values.

[0034] According to the present invention, in order to further improve the efficiency and yield of preparing in vitro thrombi, preferably, in step (2), the solvent is a buffer solution, which can be a buffer solution conventionally selected in the art, such as Tris-HCl buffer solution, PBS buffer solution, or acetate-sodium acetate buffer solution, and more preferably Tris-HCl buffer solution. Specifically, the pH of the Tris-HCl buffer solution is 7-8.

[0035] According to the present invention, the addition of a soluble calcium salt can increase the concentration of calcium ions in plasma, causing fibrinogen to convert to fibrin, thereby improving the efficiency of in vitro thrombus preparation. The soluble calcium salt can be any calcium salt conventionally selected in the art, to further improve the efficiency of in vitro thrombus preparation. Preferably, the soluble calcium salt is selected from at least one of calcium chloride, calcium nitrate, and calcium sulfate, and more preferably calcium chloride.

[0036] According to the present invention, preferably, the amount of mixture I added relative to 1 mL of the solvent is 0.8-0.9 mL, specifically 0.8 mL, 0.85 mL, 0.9 mL, or any value between the two aforementioned values; the thrombin activity is 0.3-0.6 U, specifically 0.3 U, 0.4 U, 0.5 U, 0.6 U, or any value between the two aforementioned values; the amount of soluble calcium salt added is 6-8 μmol, specifically 6 μmol, 7 μmol, 8 μmol, or any value between the two aforementioned values. The inventors have found that, under this preferred embodiment, the synergistic effect of the solvent, mixture I, thrombin, and soluble calcium salt can further improve the yield and productivity of in vitro thrombi.

[0037] According to the present invention, in order to further improve the yield of in vitro thrombus, preferably, the incubation conditions include at least: a temperature of 35-40°C, specifically 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, or any value between the two aforementioned values; and a time of 1-3 hours, specifically 1 hour, 2 hours, 3 hours, or any value between the two aforementioned values.

[0038] According to the present invention, in order to further improve the yield of in vitro thrombi, preferably, the concentration of glutaraldehyde in the glutaraldehyde solution is 2-3% by volume, specifically 2% by volume, 2.5% by volume, 3% by volume, or any value between the two aforementioned values. The solvent used in the glutaraldehyde solution is water.

[0039] According to the present invention, in order to further improve the yield of in vitro thrombus, preferably, the fixed conditions include at least: a temperature of 25-30°C; specifically, it can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, or any value between the two aforementioned values; and a time of 2-4 hours; specifically, it can be 2 hours, 3 hours, 4 hours, or any value between the two aforementioned values.

[0040] In this invention, the method further includes: washing the obtained plasma clot and mixing it with glutaraldehyde solution, then fixing, washing, and freeze-drying it to obtain an in vitro thrombus. Exemplarily, the method further includes: washing the plasma clot 2-5 times with Tris-HCl buffer solution, fixing it with glutaraldehyde solution, washing it 2-5 times with Tris-HCl buffer solution, placing it at room temperature for 2-3 hours, and then freeze-drying it to obtain an in vitro thrombus.

[0041] According to the present invention, preferably, in step (3), the thrombolytic enzyme is selected from at least one of urokinase, nattokinase, streptokinase, alteplase, and reteplase, and more preferably urokinase. The inventors have found that, under this preferred embodiment, the degradation efficiency of the thrombolytic enzyme on thrombi in in vitro thrombi can be improved.

[0042] According to the present invention, in order to further improve the degradation efficiency of thrombolytic enzyme on thrombi in in vitro thrombus blocks, preferably, the enzyme activity of the thrombolytic enzyme is 1-2 U relative to 1 mL of the physiological saline, specifically 1 U, 1.5 U, 2 U, or any value between the two aforementioned values; the amount of the in vitro thrombus block is 0.5-1.0 g, specifically 0.5 g, 0.6 g, 0.7 g, 0.8 g, 0.9 g, 1.0 g, or any value between the two aforementioned values.

[0043] According to the present invention, in order to further improve the degradation efficiency of thrombolytic enzymes on thrombi in in vitro thrombus masses, preferably, the degradation conditions include at least: a temperature of 35-40°C, specifically 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, or any value between the two aforementioned values; and a time of 6-24h, specifically 6h, 12h, 18h, 24h, or any value between the two aforementioned values.

[0044] According to the present invention, in order to further improve the accuracy of thrombus structure detection, preferably, in step (4), the structure of the thrombus is analyzed by scanning electron microscopy; before detection, 6-10 nm of metallic palladium is sprayed onto the degraded in vitro thrombus block.

[0045] In this invention, the process of detecting thrombus structures using scanning electron microscopy includes: measuring the pore size and number of fibrin fibers within fibrin fibers using ImageJ; measuring the pore size at the widest point of all samples, and selecting one representative image for each sample for measurement.

[0046] According to the present invention, preferably, the structure of the thrombus is observed using a fluorescence microscope.

[0047] According to the present invention, preferably, a fluorescence spectrophotometer is used to detect the plasma fluorescence intensity of the degraded in vitro thrombus.

[0048] According to a particularly preferred embodiment of the present invention, a method for detecting in vitro thrombolysis is provided, the method comprising the following steps: (1) Fluorescent labeling of fibrinogen with fluorescein to obtain fluorescein-labeled fibrinogen, and mixing the fluorescein-labeled fibrinogen with plasma to obtain mixture I; (2) Mix the mixture I, thrombin, soluble calcium salt and solvent, and incubate at 35-40℃ for 1-3h to obtain a plasma clot; mix the plasma clot with glutaraldehyde solution and fix at 25-30℃ for 2-4h to obtain an in vitro thrombus. (3) The in vitro thrombus, thrombolytic enzyme and physiological saline are mixed and degraded at a temperature of 35-40℃ for 6-24 hours to obtain the degraded in vitro thrombus; (4) Determine the structure of the thrombus in the degraded in vitro thrombus and analyze the relationship between the structure of the thrombus and thrombus degradation; detect the plasma fluorescence intensity of the degraded in vitro thrombus and analyze the relationship between the plasma fluorescence intensity and thrombus degradation. In step (1), the fluorescein is FITC and / or TRITC, the plasma is selected from at least one of mouse plasma, canine plasma and human plasma, and the volume ratio of the fluorescein-labeled fibrinogen to the plasma is 1:3-7; the mixture I obtained in step (1) is diluted 4-8 times with physiological saline. In step (2), the solvent is Tris-HCl buffer solution, and the soluble calcium salt is calcium chloride; relative to 1 mL of the solvent, the amount of mixture I added is 0.8-0.9 mL, the enzyme activity of the thrombin is 0.3-0.6 U, and the amount of the soluble calcium salt added is 6-8 μmol; In step (3), the thrombolytic enzyme is urokinase; relative to 1 mL of the physiological saline, the enzyme activity of the thrombolytic enzyme is 1-2 U, and the amount of the in vitro thrombus is 0.5-1.0 g; In step (4), the structure of the thrombus is analyzed by scanning electron microscopy; before detection, 6-10 nm of palladium is sprayed onto the degraded in vitro thrombus block; the structure of the thrombus is observed by fluorescence microscopy; and the plasma fluorescence intensity of the degraded in vitro thrombus block is detected by fluorescence spectrophotometer.

[0049] In the preferred embodiment described above, an in vitro thrombus block is prepared by labeling fibrinogen with fluorescein, and the thrombus in the in vitro thrombus block is fluorescently labeled. During the degradation process of the in vitro thrombus block, thrombolytic enzyme, and physiological saline, the dissolution of the thrombus can be detected rapidly and sensitively based on the structure of the fluorescently labeled thrombus.

[0050] The present invention will be described in detail below with reference to embodiments, but this does not limit the scope of the invention.

[0051] Unless otherwise specified, all materials used in the following examples and comparative examples are commercially available. The scanning electron microscope is model SU5000, manufactured by Hitachi. The laser scanning confocal microscope is model TCS SP8, manufactured by Leica. The fluorescence spectrophotometer is model BioTek Synergy 2, manufactured by Berten.

[0052] Example 1 (1) FITC was used to fluorescently label fibrinogen to obtain fluorescently labeled fibrinogen (FITC-fibrinogen); FITC-fibrinogen and plasma of C57BL / 6J mice were mixed at a volume ratio of 1:3 to obtain mixture I; (2) Preparation of in vitro thrombus: Mixed plasma (mixed solution I and physiological saline were diluted at a volume ratio of 1:4) was mixed with thrombin, calcium chloride and Tris-HCl buffer, and incubated at 37°C for 2 h (the enzyme activity of thrombin was 0.3 U, the amount of calcium chloride added was 6 μmol, and the amount of mixed plasma added was 0.8 mL relative to 1 mL Tris-HCl buffer) to obtain plasma clots; the plasma clots were washed with Tris-HCl buffer (50 mM, 100 mM NaCl, pH 7.4), fixed with 2.0 vol% glutaraldehyde solution for 2 h, washed 3 times with Tris-HCl buffer, and lyophilized at room temperature for 2 h to obtain in vitro thrombus clots; (3) Thrombus degradation reaction: Urokinase and physiological saline were added to the in vitro thrombus block (the enzyme activity of urokinase was 1U relative to 1mL of physiological saline, and the amount of in vitro thrombus block was 0.5g), and the reaction was carried out for 6 hours before detection. (4) Thrombus structure analysis: 6nm gold-plated palladium was sprayed onto the degraded in vitro thrombus obtained in step (3), and the thrombus was detected by field emission scanning electron microscopy. The pore size and number of fibrin fibers in the fibrin fibers were measured using ImageJ. The pore size was measured at the widest point of all samples. One representative image of each sample was selected for measurement. The structure of the thrombus was analyzed by scanning electron microscopy. The structure of the thrombus was observed by confocal fluorescence microscopy, and the relationship between the structural characteristics of the thrombus and thrombus degradation was analyzed. (5) Detection of in vitro thrombolysis: The fluorescence intensity of plasma was detected by a fluorescence spectrophotometer, and the relationship between plasma fluorescence intensity and thrombus degradation was analyzed.

[0053] Example 2 (1) FITC was used to fluorescently label fibrinogen to obtain fluorescently labeled fibrinogen (FITC-fibrinogen); FITC-fibrinogen and beagle plasma were mixed at a volume ratio of 1:5 to obtain mixture I; (2) Preparation of in vitro thrombi: Mixed plasma (mixed solution I and physiological saline were diluted at a volume ratio of 1:6) was mixed with thrombin, calcium chloride and Tris-HCl buffer, and incubated at 35°C for 2 h (the enzyme activity of thrombin was 0.5 U, the amount of calcium chloride added was 7 μmol, and the amount of mixed plasma added was 0.85 mL relative to 1 mL Tris-HCl buffer) to obtain plasma clots; the plasma clots were washed with Tris-HCl buffer (50 mM, 100 mM NaCl, pH 7.4), fixed with 2.5 volume % glutaraldehyde solution at 25°C for 3 h, washed 3 times with Tris-HCl buffer, and lyophilized at room temperature for 3 h to obtain in vitro thrombi; (3) Thrombus degradation reaction: Urokinase and physiological saline were added to the in vitro thrombus block (the enzyme activity of urokinase was 1.5U relative to 1mL of physiological saline, and the amount of in vitro thrombus block was 0.75g), and the reaction was carried out at 25℃ for 12 hours before detection. (4) Thrombus structure analysis: 8nm gold-plated palladium was sprayed onto the degraded in vitro thrombus obtained in step (3), and the thrombus was detected by field emission scanning electron microscopy. The pore size and number of fibrin fibers in the fibrin fibers were measured using ImageJ. The pore size was measured at the widest point of all samples. One representative image of each sample was selected for measurement. The structure of the thrombus was analyzed by scanning electron microscopy. The structure of the thrombus was observed by confocal fluorescence microscopy, and the relationship between the structural characteristics of the thrombus and thrombus degradation was analyzed. (5) Detection of in vitro thrombolysis: The fluorescence intensity of plasma was detected by a fluorescence spectrophotometer, and the relationship between plasma fluorescence intensity and thrombus degradation was analyzed.

[0054] Example 3 (1) FITC was used to fluorescently label fibrinogen to obtain fluorescently labeled fibrinogen (FITC-fibrinogen); FITC-fibrinogen and human plasma were mixed at a volume ratio of 1:7 to obtain mixture I; (2) Preparation of in vitro thrombus: Mixed plasma (mixed solution I and physiological saline were diluted at a volume ratio of 1:8) was mixed with thrombin, calcium chloride and Tris-HCl buffer, and incubated at 40°C for 3 h (the enzyme activity of thrombin was 0.6 U, the amount of calcium chloride added was 8 μmol, and the amount of mixed plasma added was 0.875 mL relative to 1 mL Tris-HCl buffer) to obtain plasma clots; the plasma clots were washed with Tris-HCl buffer (50 mM, 100 mM NaCl, pH 7.4), fixed with 3.0 v / v glutaraldehyde solution at 30°C for 4 h, washed 5 times with Tris-HCl buffer, and lyophilized at room temperature for 4 h to obtain in vitro thrombus clots; (3) Thrombus degradation reaction: Urokinase and physiological saline were added to the in vitro thrombus block (the enzyme activity of urokinase was 2U relative to 1mL of physiological saline, and the amount of in vitro thrombus block was 1.0g), and the reaction was carried out at 30℃ for 24 hours before detection. (4) Thrombus structure analysis: 10 nm gold-plated palladium was sprayed onto the degraded in vitro thrombus obtained in step (3), and the thrombus was detected by field emission scanning electron microscopy. The pore size and number of fibrin fibers in the fibrin fibers were measured using ImageJ. The pore size was measured at the widest point of all samples. One representative image of each sample was selected for measurement. The structure of the thrombus was analyzed by scanning electron microscopy. The structure of the thrombus was observed by confocal fluorescence microscopy, and the relationship between the structural characteristics of the thrombus and thrombus degradation was analyzed. (5) Detection of in vitro thrombolysis: The fluorescence intensity of plasma was detected by a fluorescence spectrophotometer, and the relationship between plasma fluorescence intensity and thrombus degradation was analyzed.

[0055] Example 4 The in vitro thrombolysis was detected according to the method of Example 1, except that in step (1), FITC was replaced with propidium iodide (PI).

[0056] Example 5 The in vitro thrombolysis was detected according to the method of Example 1, except that in step (1), the volume ratio of FITC-fibrinogen to mouse plasma was replaced with 1:15.

[0057] Example 6 The in vitro thrombolysis was detected according to the method of Example 1, except that step (2) was replaced with: (2) Preparation of in vitro thrombus: Mixture I was mixed with thrombin, calcium chloride and Tris-HCl buffer and incubated at 37°C for 2 h (the enzyme activity of thrombin was 0.5 U relative to 1 mL Tris-HCl buffer, the amount of calcium chloride added was 7 μmol, and the amount of mixture I added was 0.9 mL) to obtain plasma clots; the plasma clots were washed with Tris-HCl buffer (50 mM, 100 mM NaCl, pH 7.4), fixed with 2.5 vol% glutaraldehyde solution for 3 h, washed 3 times with Tris-HCl buffer, and lyophilized at room temperature for 3 h to obtain in vitro thrombus clots.

[0058] Example 7 The in vitro thrombolysis was detected according to the method of Example 1, except that in step (2), the Tris-HCl buffer solution was replaced with PBS buffer solution and the calcium chloride was replaced with calcium sulfate.

[0059] Example 8 The in vitro thrombolysis was detected according to the method of Example 1, except that in step (3), urokinase was replaced with alteplase.

[0060] Comparative Example 1 The in vitro thrombolysis was detected according to the method of Example 1, except that step (1) was replaced with: (1) Fibrinogen and mouse plasma were mixed at a volume ratio of 1:3 to obtain mixture I.

[0061] Comparative Example 2 The in vitro thrombolysis was detected according to the method of Example 1, except that step (1) was replaced with: (3) Thrombus degradation reaction: add physiological saline to the in vitro thrombus (the amount of in vitro thrombus is 1.0g relative to 1mL of physiological saline), and test after 12 hours.

[0062] Comparative Example 3 The in vitro thrombolysis was detected according to the method of Example 1, except that step (2) was replaced with: (2) Preparation of in vitro thrombus: Mixed plasma (mixed solution I and physiological saline were diluted at a volume ratio of 1:4) was mixed with thrombin, calcium chloride and Tris-HCl buffer, and incubated at 37°C for 2 h (the enzyme activity of thrombin was 0.3 U, the amount of calcium chloride added was 6 μmol, and the amount of mixed plasma added was 0.8 mL relative to 1 mL Tris-HCl buffer) to obtain plasma clots; the plasma clots were washed with Tris-HCl buffer (50 mM, 100 mM NaCl, pH 7.4), and after being placed at room temperature for 2 hours, they were freeze-dried to obtain in vitro thrombus clots.

[0063] Test case The structures of the degraded in vitro thrombi from Examples 2, 3, and Comparative Example 2 were examined using field emission scanning electron microscopy. The results are shown in the figures below. Figure 1 , Figure 2 and Figure 3 .

[0064] The structures of the degraded in vitro thrombi from Examples 2, 3, and Comparative Example 2 were examined using confocal fluorescence microscopy. The results are shown in the figures below. Figure 4 , Figure 5 and Figure 6 .

[0065] Depend on Figures 1-3 It can be seen that the diameter of the thrombus fibers gradually increases, the distance between the protofibrils gradually widens, and the number of protofibrils decreases.

[0066] Depend on Figures 4-6 It can be seen that there are significant differences in the fibrin network structure. Figure 6 and Figure 4 , 5 In contrast, fibrin forms a fibrous region with a less dense fiber arrangement and branching points.

[0067] The preferred embodiments of the present invention have been described in detail above; however, the present invention is not limited thereto. Within the scope of the inventive concept, various simple modifications can be made to the technical solutions of the present invention, including combinations of various technical features in any other suitable manner. These simple modifications and combinations should also be considered as the content disclosed in the present invention and are all within the protection scope of the present invention.

Claims

1. A method of detecting thrombus dissolution in vitro, characterized in that, The method includes the following steps: (1) Fluorescent labeling of fibrinogen with fluorescein to obtain fluorescein-labeled fibrinogen, and mixing the fluorescein-labeled fibrinogen with plasma to obtain mixture I; (2) Mix the above-mentioned mixture I, thrombin, soluble calcium salt and solvent and incubate to obtain a plasma clot; mix the plasma clot with glutaraldehyde solution and fix it to obtain an in vitro thrombus; (3) The in vitro thrombus, thrombolytic enzyme and physiological saline are mixed and degraded to obtain the degraded in vitro thrombus; (4) Determine the structure of the thrombus in the degraded in vitro thrombus and analyze the relationship between the structure of the thrombus and thrombus degradation; detect the plasma fluorescence intensity of the degraded in vitro thrombus and analyze the relationship between the plasma fluorescence intensity and thrombus degradation. In step (2), the solvent is Tris-HCl buffer solution, the soluble calcium salt is calcium chloride, the amount of mixture I added relative to 1 mL of the solvent is 0.8-0.9 mL, the enzyme activity of the thrombin is 0.3-0.6 U, the amount of the soluble calcium salt added is 6-8 μmol, the incubation conditions include at least: temperature of 35-40℃, time of 1-3 h; the concentration of glutaraldehyde in the glutaraldehyde solution is 2-3% by volume, and the fixation conditions include at least: temperature of 25-30℃, time of 2-4 h; In step (4), the structure of the thrombus is analyzed by scanning electron microscopy; before detection, 6-10 nm of palladium is sprayed onto the degraded in vitro thrombus block; and the plasma fluorescence intensity of the degraded in vitro thrombus block is detected by fluorescence spectrophotometer.

2. The method of claim 1, wherein, In step (1), the fluorescein is FITC and / or TRITC.

3. The method of claim 2, wherein, The plasma is selected from at least one of rat plasma, dog plasma, and human plasma.

4. The method of claim 2, wherein, The volume ratio of the fluorescein-labeled fibrinogen to the plasma is 1:3-7.

5. The method according to claim 1, characterized in that, The method further includes: diluting the mixture I obtained in step (1) with physiological saline by 4-8 times.

6. The method according to any one of claims 1 to 5, characterized in that, In step (3), the thrombolytic enzyme is selected from at least one of urokinase, nattokinase, streptokinase, alteplase and reteplase.

7. The method according to claim 6, characterized in that, The thrombolytic enzyme is urokinase.

8. The method according to claim 7, characterized in that, The thrombolytic enzyme has an activity of 1-2 U relative to 1 mL of the physiological saline, and the amount of the in vitro thrombus is 0.5-1.0 g.

9. The method according to claim 8, characterized in that, The degradation conditions include at least the following: a temperature of 35-40°C and a time of 6-24 hours.

10. The method according to any one of claims 1 to 5, characterized in that, In step (4), the structure of the thrombus is observed using a fluorescence microscope.

Citation Information

Patent Citations

  • Reporter labeled annular clot system for diagnosis and research

    WO2023014866A1